

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. According to updated overall survival analysis, what was the approximate reduction in risk of death among patients receiving trastuzumab deruxtecan versus treatment of physician's choice for HR-positive HER2-low metastatic breast cancer on the Phase III DESTINY-Breast04 study?
 - a. 0%
 - b. 11%
 - c. 31%
 - d. 51%
2. Extended adjuvant therapy with neratinib has demonstrated greater clinical efficacy among which of the following subsets of patients with HER2-positive breast cancer?
 - a. Patients with ER-negative disease
 - b. Patients with ER-positive disease
 - c. Both a and b
 - d. Neither a nor b
3. Which of the following adverse events is most frequently observed with datopotamab deruxtecan?
 - a. Hypertension
 - b. Ocular disorder
 - c. Pleural effusion
 - d. Rash
 - e. Stomatitis
4. Patritumab deruxtecan targets which of the following receptors?
 - a. NRG1
 - b. MET
 - c. HER2
 - d. HER3
 - e. CEACAM5
 - f. TROP2
5. Findings from the Phase III ALEXANDRA/IMpassion030 trial of adjuvant atezolizumab with anthracycline/taxane chemotherapy versus chemotherapy alone for patients with localized triple-negative breast cancer demonstrated which of the following outcomes with the addition of adjuvant atezolizumab?
 - a. Median disease-free survival (DFS) benefit with the addition of adjuvant atezolizumab
 - b. Median DFS equivalence between the study arms
 - c. Median DFS detriment with the addition of adjuvant atezolizumab